Business
ARS Pharmaceuticals - neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions
ARS Pharmaceuticals - neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic
About this update from Ars Pharmaceuticals, Inc.
SAN DIEGO - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China , the trade name is ??? meaning 'Excellent Allergy (treatment) Fast'e> 30 December 2025 / (C) 2025 Electronic News Publishing, source ENP Newswire
View stock analysis, news, and events for Ars Pharmaceuticals, Inc.
More from Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Res...
August 13, 2026
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Qu...
August 3, 2026